Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Editor in Chief
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
2
result was found. Results that relate to
PEI Ruifeng
Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma
Published on
Frontiers in Pharmaceutical Sciences
2024,27(1):109-116.
921 times
416 times
SU Zhan
CHE Jinhui
PEI Ruifeng
Hepatocellular carcinoma
Tislelizumab
Sorafenib
Partition survival model
Pharmacoeconomic analysis
Details
Real-world study of sintilimab combined with bevacizumab in patients with advanced hepatocellular carcinoma
Published on
Frontiers in Pharmaceutical Sciences
2024,27(3):485-490.
971 times
663 times
SU Zhan
CHE Jinhui
PEI Ruifeng
Advanced hepatocellular carcinoma
Sintilimab
Bevacizumab
Clinical efficacy
Safety
Overall survival
Progression-free survival
Details
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University